Literature DB >> 1346381

Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors.

M I Goth1, C E Lyons, B J Canny, M O Thorner.   

Abstract

GH secretion has been thought traditionally to be regulated by the two hypothalamic hormones, GH-releasing hormone (GHRH) and somatostatin (SRIF). Recent evidence has suggested that other factors may be involved. These factors include the natural ligand for the synthetic hexapeptide GH-releasing peptide (GHRP) and the putative hypophysiotropic factor pituitary adenylate cyclase-activating polypeptide (PA-CAP). Accordingly, we examined the effects of GHRP and PACAP on GH secretion at the single cell level using the reverse hemolytic plaque assay which allows distinction of effects on the number of secreting cells and the amount of hormone each cell secretes. Both factors stimulated GH secretion in a dose-dependent fashion, with PACAP being more effective. PACAP increased both the number of cells secreting and the mean amount of hormone secreted per cell. In contrast, GHRP increased the number of secreting cells, although it had no effect on the amount of secretion per cell. GH secretion induced by GHRH, GHRP, and PACAP was inhibited by SRIF, but the effect was predominantly on the number of cells secreting rather than the amount secreted per cell. Specific antagonists to GHRP and GHRH inhibited GH secretion induced by the respective agonist but not that induced by the other factor nor by PACAP. These findings confirm the complex nature of the regulation of GH secretion at the level of the somatotrope. At least three factors, operating via distinct receptors, are able to increase GH secretion. In addition, they ascribe a potential physiological role for the hitherto putative hypophysiotropic factor PACAP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346381     DOI: 10.1210/endo.130.2.1346381

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  28 in total

1.  Pituitary adenylate cyclase-activating polypeptide inhibits transforming growth factor-beta1-induced apoptosis in a human pituitary adenoma cell line.

Authors:  H Oka; L Jin; E Kulig; B W Scheithauer; R V Lloyd
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

Authors:  R S McDowell; K A Elias; M S Stanley; D J Burdick; J P Burnier; K S Chan; W J Fairbrother; R G Hammonds; G S Ingle; N E Jacobsen; D L Mortensen; T E Rawson; W B Won; R G Clark; T C Somers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

4.  Effects of acute administration of growth hormone-releasing hormone (GHRH) and oxytocin on somatotroph cells in sheep: morphometric study and growth hormone (GH) secretion.

Authors:  M Rico; S Vidal; M T Lorenzo; L Moya; L F De la Cruz
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

5.  Gap junction-mediated cell-to-cell communication in bovine and human adrenal cells. A process whereby cells increase their responsiveness to physiological corticotropin concentrations.

Authors:  Y Munari-Silem; M C Lebrethon; I Morand; B Rousset; J M Saez
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Lack of effect of hexarelin on TRH-induced TSH response in normal adult man.

Authors:  M Arosio; G Casati; O Biella; S Porretti; B P Imbimbo; G Faglia
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

Review 7.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

8.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

9.  Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas.

Authors:  H Oka; L Jin; J C Reubi; X Qian; B W Scheithauer; K Fujii; T Kameya; R V Lloyd
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

Authors:  J R Pisegna; S A Wank
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.